MEDICAL DEVICE DEVELOPERS HAVE BEEN COMPELLED TO OUTSOURCE THEIR MANUFACTURING OPERATIONS TO CONTRACT SERVICE PROVIDERS

The in-house development of peptide API requires necessary expertise and capabilities, including design, construction and maintenance of a facility which demands significant capital investments. Therefore, several small drug developers and, at times, certain pharma giants as well, have started outsourcing their manufacturing operations to contract service providers.

Over the years, the popularity of biologics has led to an evident shift in the focus of pharmaceutical companies, from traditional interventions towards more complex and advanced pharmacological interventions, such as peptide therapeutics. Since the discovery of insulin, the peptide therapeutics market has evolved significantly.

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen